Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (131-140 of 487) with videos related to

Pageof 49
Sort By:
Journal of Comparative Effectiveness Research|July 29, 2023
For what it's worth: the complex area of medicine value assessmentSreeram V Ramagopalan, Catrin Treharne, Jonathan Pearson-Stuttard, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 14, 2025
Designing Clinical Trials for Patients With Rare Cancers: Connecting the ZebrasVivek Subbiah, Megan Othus, Jim Palma, et al.
The Lancet. Oncology|January 1, 2022
Assessment of tumour-agnostic therapies in basket trialsSanjay Popat, Sreeram V Ramagopalan, Joshua Ray, et al.
Cancer Discovery|April 18, 2023
N-of-1 Trials in Cancer Drug DevelopmentMohamed A Gouda, Lars Buschhorn, Andreas Schneeweiss, et al.
Pediatric Blood & Cancer|September 17, 2011
Advanced atypical teratoid/rhabdoid tumor (ATRT) treated with intensive multimodal approach shows continued response to sarcoma type salvage therapyVivek Subbiah, Johannes Wolff, Leena Ketonen, et al.
The Lancet. Oncology|November 5, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer - Authors' replyVivek Subbiah, Ulrik Lassen, Eduard Gasal, et al.
Med (New York, N.Y.)|March 9, 2023
The abscopal effect in patients with cancer receiving immunotherapyBlessie Elizabeth Nelson, Jacob J Adashek, Steven H Lin, et al.
Experimental Hematology & Oncology|July 11, 2025
Advancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancerEdwin Lin, Ying-Chun Lo, Vivek Subbiah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent CancersVivek Subbiah, Dong Yang, Vamsidhar Velcheti, et al.
Cancer Medicine|November 22, 2022
On target methods to induce abscopal phenomenon for Off-Target effects: From happenstance to happeningsBlessie Elizabeth Nelson, Jacob J Adashek, Steven H Lin, et al.
Pageof 49

Showing results (131-140 of 487) with videos related to

Sort By:
Pageof 49
Journal of Comparative Effectiveness Research|July 29, 2023
For what it's worth: the complex area of medicine value assessmentSreeram V Ramagopalan, Catrin Treharne, Jonathan Pearson-Stuttard, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 14, 2025
Designing Clinical Trials for Patients With Rare Cancers: Connecting the ZebrasVivek Subbiah, Megan Othus, Jim Palma, et al.
The Lancet. Oncology|January 1, 2022
Assessment of tumour-agnostic therapies in basket trialsSanjay Popat, Sreeram V Ramagopalan, Joshua Ray, et al.
Cancer Discovery|April 18, 2023
N-of-1 Trials in Cancer Drug DevelopmentMohamed A Gouda, Lars Buschhorn, Andreas Schneeweiss, et al.
Pediatric Blood & Cancer|September 17, 2011
Advanced atypical teratoid/rhabdoid tumor (ATRT) treated with intensive multimodal approach shows continued response to sarcoma type salvage therapyVivek Subbiah, Johannes Wolff, Leena Ketonen, et al.
The Lancet. Oncology|November 5, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer - Authors' replyVivek Subbiah, Ulrik Lassen, Eduard Gasal, et al.
Med (New York, N.Y.)|March 9, 2023
The abscopal effect in patients with cancer receiving immunotherapyBlessie Elizabeth Nelson, Jacob J Adashek, Steven H Lin, et al.
Experimental Hematology & Oncology|July 11, 2025
Advancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancerEdwin Lin, Ying-Chun Lo, Vivek Subbiah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent CancersVivek Subbiah, Dong Yang, Vamsidhar Velcheti, et al.
Cancer Medicine|November 22, 2022
On target methods to induce abscopal phenomenon for Off-Target effects: From happenstance to happeningsBlessie Elizabeth Nelson, Jacob J Adashek, Steven H Lin, et al.
Pageof 49